Atrial tachycardia is a supraventricular tachycardia (SVT) that does not require the atrioventricular (AV) junction, accessory pathways, or ventricular tissue for its initiation and maintenance. It occurs in persons with normal heaRTS and in those with structurally abnormal heaRTS, including individuals with congenital heart disease (particularly after surgery for repair or correction of congenital or valvular heart disease). See the image below.
In patients with structurally normal heaRTS, atrial tachycardia is associated with a low mortality rate. Patients with underlying structural heart disease, congenital heart disease, or lung disease are less likely to be able to tolerate this rhythm disturbance.
Manifestations of atrial tachycardia include the following:
Rapid pulse rate: In most atrial tachycardias, the rapid pulse is regular; it may be irregular in rapid atrial tachycardias with variable AV conduction and in multifocal atrial tachycardia (MAT)
Episodic or paroxysmal occurrence
Sudden onset of palpitations
Continuous, sustained, or repetitive tachycardia: If atrial tachycardia is due to enhanced automaticity
Warm-up phenomenon: Tachycardia gradually speeds up soon after onset (may be clinically inapparent)
Dyspnea, dizziness, lightheadedness, fatigue, or chest pressure: In tachycardic episodes accompanied by palpitations
Syncope: With rapid rate and severe hypotension
Heart-failure symptoms and reduced effort tolerance: Early manifestations of tachycardia-induced cardiomyopathy in patients with frequent or incessant tachycardia
In patients with MAT, the history may disclose an underlying illness that is causing the tachycardia. Such illnesses include pulmonary, cardiac, metabolic, and endocrinopathic disorders. Chronic obstructive pulmonary disease (Copd) is the most common underlying disease process (60%) in MAT.
Reentrant atrial tachycardia is not uncommon in patients with a history of a surgically repaired atrial septal defect. The scar tissue in the atrium may give rise to the formation of a reentrant circuit.
On physical examination, the primary abnormal finding is a rapid pulse rate. The rate is usually regular, but it may be irregular in rapid atrial tachycardias with variable AV conduction and in MAT. Blood pressure may be low in patients presenting with fatigue, lightheadedness, or presyncope.
See Clinical Presentation for more detail.
Workup for atrial tachycardia can employ the following diagnostic tools:
12-lead electrocardiography with rhythm strip: To help identify, locate, and differentiate atrial tachycardia
Holter monitoring: To analyze the onset and termination of atrial tachycardia, identify the AV conduction block during the episode, and correlate the symptoms to atrial tachycardia
Endocardial mapping: To localize atrial tachycardia
The following laboratory studies may be indicated to exclude systemic causes of sinus tachycardia:
Serum chemistry: To exclude electrolyte disorders
Blood hemoglobin level and red blood cell (RBC) counts: To seek evidence of anemia
Arterial blood gas level: To define pulmonary status
Serum digoxin assay: When digitalis intoxication is suspected
The following imaging studies can be useful in the evaluation of patients with atrial tachycardia:
Chest radiography: In patients with tachycardia-induced cardiomyopathy or complex congenital heart disease
Computed tomography (CT) scanning: To exclude pulmonary embolism, assess the anatomy of pulmonary veins, and provide images prior to ablative procedure
Echocardiography: To rule out structural heart disease and assess left atrial size, pulmonary arterial pressure, left ventricular function, and pericardial pathology
See Workup for more detail.
The primary treatment during a bout of atrial tachycardia is considered to be rate control using AV nodal blocking agents (eg, beta-blockers, calcium channel blockers). Antiarrhythmic drugs can prevent recurrences and may be required; a calcium channel blocker or beta-blocker also may be required in combination therapy. Specific antiarrhythmic therapies include the following:
Atrial tachycardia from triggered activity: Verapamil, beta-blockers, and adenosine
Atrial tachycardia from enhanced automaticity: Beta-blockers, but overall success rates are low
Refractory recurrent atrial tachycardia: Class Ic antiarrhythmic drugs
Maintenance of sinus rhythm: Class III antiarrhythmic drugs
Nonpharmacologic therapies for atrial tachycardia include the following:
Cardioversion: For patients in whom the rhythm is not well-tolerated hemodynamically and/or in whom rate-control drugs are ineffective or contraindicated
Surgical ablation: For patients with complex congenital heart disease
Multifocal atrial tachycardia
Treatment of MAT involves treatment and/or reversal of the precipitating cause. Therapy also may include the following:
Calcium channel blockers: Used as the first line of treatment
Magnesium sulfate: When administered to correct hypokalemia, most patients convert to normal sinus rhythm (NSR)
In very rare cases, when MAT is persistent and refractory, AV junctional radiofrequency ablation and permanent pacemaker implantation should be considered. Such treatment can provide symptomatic and hemodynamic improvement and prevent the development of tachycardia-mediated cardiomyopathy.  In general, short and asymptomatic runs of atrial tachycardia detected as an incidental finding on ambulatory ECG do not require treatment.
Atrial tachycardia is defined as a supraventricular tachycardia (SVT) that does not require the atrioventricular (AV) junction, accessory pathways, or ventricular tissue for its initiation and maintenance. Atrial tachycardia can be observed in persons with normal heaRTS and in those with structurally abnormal heaRTS, including those with congenital heart disease and particularly after surgery for repair or correction of congenital or valvular heart disease.
In adults, tachycardia is usually defined as a heart rate more than 100 beats per minute (bpm). In children, the definition of tachycardia varies because the normal heart rate is age dependent, as follows: [4, 5]
Age 1-2 days: 123-159 bpm
Age 3-6 days: 129-166 bpm
Age 1-3 weeks: 107-182 bpm
Age 1-2 months: 121-179 bpm
Age 3-5 months: 106-186 bpm
Age 6-11 months: 109-169 bpm
Age 1-2 years: 89-151 bpm
Age 3-4 years: 73-137 bpm
Age 8-11 years: 62-130 bpm
Age 12-15 years: 60-119 bpm
As in most SVTs, the electrocardiogram (ECG) typically shows a narrow QRS complex tachycardia (unless bundle branch block aberration occurs). Heart rates are highly variable, with a range of 100-250 bpm. The atrial rhythm is usually regular. (See the image below.)
The conducted ventricular rhythm is also usually regular. It may become irregular, however, especially at higher atrial rates, because of variable conduction through the AV node, thus producing conduction patterns such as 2:1, 4:1, a combination of those, or Wenckebach AV block.
The P wave morphology on the ECG may give clues to the site of origin and mechanism of the atrial tachycardia. In the case of a focal tachycardia, the P wave morphology and axis depend on the location in the atrium from which the tachycardia originates. In the case of macroreentrant circuits, the P wave morphology and axis depend on activation patterns (see Workup).
Multifocal atrial tachycardia (MAT) is an arrhythmia with an irregular atrial rate greater than 100 bpm. Atrial activity is well organized, with at least 3 morphologically distinct P waves, irregular P-P intervals, and an isoelectric baseline between the P waves.  Multifocal atrial tachycardia has previously been described by names such as chaotic atrial rhythm or tachycardia, chaotic atrial mechanism, and repetitive paroxysmal MAT. Go to Multifocal Atrial Tachycardia for more complete information on this topic.
A number of methods are used to classify atrial tachycardia. Classification in terms of origin can be based on endocardial activation mapping data, pathophysiologic mechanisms, and anatomy.
On the basis of endocardial activation, atrial tachycardia may be divided into the following 2 groups (see Presentation):
Focal atrial tachycardia: Arises from a localized area in the atria such as the crista terminalis, pulmonary veins, ostium of the coronary sinus, or intra-atrial septum.
Reentrant atrial tachycardias: Usually macroreentrant; reentrant atrial tachycardias most commonly occur in persons with either structural or complex heart disease, particularly after surgery involving atrial incisions or scarring
Other methods of classification are as follows:
Pathophysiologic mechanisms: Atrial tachycardia can be classified as the result of enhanced automaticity, triggered activity, or reentry (see Pathophysiology)
Anatomy: Classification of atrial tachycardia can be based on the location of the arrhythmogenic focus (see Anatomy)
A 12-lead ECG with rhythm strip is an important tool to help identify, locate, and differentiate atrial tachycardia. Laboratory studies may be indicated to exclude systemic disorders that may be causing the tachycardia. Electrophysiologic study may be required. (See Workup.) The morphology of the P wave may provide valuable clues to the origin of the tachycardia, and this is the reason why a 12-lead ECG is of special value.
The primary treatment during a bout of atrial tachycardia is considered to be rate control using AV nodal blocking agents, such as beta-blockers or calcium channel blockers (see Treatment and Medication). Cardioversion should be considered for any patient in whom the rhythm is not tolerated well hemodynamically and/or in whom rate control drugs are ineffective or contraindicated.
Radiofrequency catheter ablation for atrial tachycardia has become a highly successful and effective treatment option for symptomatic patients whose condition is refractory to medical therapy or who do not desire long-term antiarrhythmic therapy. It can cure macroreentrant and focal forms of atrial tachycardia. (See Treatment.) [7, 8]
Atrial tachycardia can have a right or left atrial origin. Some atrial tachycardias actually originate outside the usual anatomic boundaries of the atria, in areas such as the superior vena cava, pulmonary veins, and vein of Marshall, where fingers of atrial myocardium extend into these locations. Rare locations, such as the noncoronary aortic cusp  and hepatic veins, have been described, as well. (See the video below.)
A number of aspects of the atrial anatomy can contribute to the substrate for arrhythmia. The orifices of the vena cava, pulmonary veins, coronary sinus, atrial septum, and mitral and tricuspid annuli are potential anatomic boundaries for reentrant circuits.
Anisotropic conduction in the atria due to complex fiber orientation may create the zone of slow conduction. Certain atrial tissues, such as the crista terminalis and pulmonary veins, are common sites for automaticity or triggered activity. Additionally, disease processes or age-related degeneration of the atria may give rise to the arrhythmogenic substrate.
Abnormalities that have been reported at the sites of atrial tachycardia origin include the following  :
Extensive myocardial fibrosis
Mononuclear cell infiltration
Mesenchymal cell proliferation
Islets of fatty tissue
Several pathophysiologic mechanisms have been ascribed to atrial tachycardia. These mechanisms can be differentiated on the basis of the pattern of onset and termination and the response to drugs and atrial pacing.
Automatic atrial tachycardia arises due to enhanced tissue automaticity and is observed in patients with structurally normal heaRTS and in those with organic heart disease. The tachycardia typically exhibits a warm-up phenomenon, during which the atrial rate gradually accelerates after its initiation and slows prior to its termination.
Automatic atrial tachycardia is rarely initiated or terminated by a single atrial stimulation or rapid atrial pacing, but it may be transiently suppressed by overdrive pacing. It almost always requires isoproterenol infusion to facilitate induction and is predictably terminated by propranolol.  Carotid sinus massage and adenosine do not terminate the tachycardia even if they produce a transient AV nodal block. Electrical cardioversion is ineffective (being equivalent to attempting electrical cardioversion in a sinus tachycardia).
Triggered activity is due to delayed after-depolarizations, which are low-amplitude oscillations occurring at the end of the action potential. These oscillations are triggered by the preceding action potential and are the result of calcium ion influxes into the myocardium. If these oscillations are of sufficient amplitude to reach the threshold potential, depolarization occurs again and a spontaneous action potential is generated.
If single, this is recognized as an atrial ectopic beat (an extra or premature beat). If it recurs and spontaneous depolarization continues, a sustained tachycardia may result.
Most commonly, atrial tachycardia due to triggered activity occurs in patients with digitalis intoxication  or conditions associated with excess catecholamines. Characteristically, the arrhythmia can be initiated, accelerated, and terminated by rapid atrial pacing. It may be sensitive to physiologic maneuvers and drugs such as adenosine, verapamil, and beta-blockers, all of which can terminate the tachycardia.
Occasionally, this atrial tachycardia may arise from multiple sites in the atria, producing a multifocal or multiform atrial tachycardia. This may be recognized by varying P wave morphology and irregularity in the atrial rhythm.
Pulmonary vein tachycardias originate from the os of the pulmonary vein or even deeper localized atrial fibers. These strands of atrial tissue are generally believed to gain electrical independence, since they are partially isolated from the atrial myocardium. These tachycardias are typically very rapid (heart rate of 200-220 bpm or more)
Although pulmonary vein tachycardias frequently trigger episodes of atrial fibrillation, the associated atrial tachycardias may be the clinically dominant or exclusive manifestation. The latter typically involves only a single pulmonary vein as opposed to the multiple pulmonary vein involvement seen in atrial fibrillation.
Intra-atrial reentry tachycardias may have either a macroreentrant or a microreentrant circuit. Macroreentry is the usual mechanism in atrial flutter and in scar- and incision-related (postsurgical) atrial tachycardia.
The more common and recognized form of atrial tachycardia, seen as a result of the advent of pulmonary vein isolation and linear ablation procedures, is left atrial tachycardia. In this situation, gaps in the ablation lines allow for slow conduction, providing the requisite anatomic substrate for reentry. These tachycardias may be self-limiting but if they persist, mapping and a repeat ablative procedure should be considered.
Microreentry can arise in a small focal area, such as in sinus node reentrant tachycardia. Typically, episodes of reentrant atrial tachycardia arise suddenly, terminate suddenly, and are paroxysmal. Carotid sinus massage and adenosine are ineffective in terminating macroreentrant tachycardias, even if they produce a transient AV nodal block. During electrophysiologic study, it can be induced and terminated by programmed extrastimulation. As is typical of other reentry tachycardias, electrical cardioversion terminates this type of atrial tachycardia.
Based on endocardial activation, atrial tachycardia may be divided into 2 groups: focal and reentrant. Focal atrial tachycardia arises from a localized area in the atria such as the crista terminalis, pulmonary veins, ostium of the coronary sinus, or intra-atrial septum. If it originates from the pulmonary veins, it may trigger atrial fibrillation and often forms a continuum of arrhythmias.
Reentrant (usually macroreentrant) atrial tachycardias most commonly occur in persons with structural heart disease or complex congenital heart disease, particularly after surgery involving incisions or scarring in the atria. Electrophysiologically, these atrial tachycardias are similar to atrial flutters, typical or atypical. Often, the distinction is semantic, typically based on arbitrary cutoffs of atrial rate.
Some tachycardias cannot be easily classified. Reentrant sinoatrial tachycardia (or sinus node reentry) is a subset of focal atrial tachycardia due to reentry arising within the sinus node situated at the superior aspect of the crista terminalis. The P wave morphology and atrial activation sequence are identical or very similar to those of sinus tachycardia.
Atrial tachycardia can occur in individuals with structurally normal heaRTS or in patients with organic heart disease. When it arises in patients with congenital heart disease who have undergone corrective or palliative cardiac surgery, such as a Fontan procedure, an atrial tachycardia can have potentially life-threatening consequences. 
The atrial tachycardia that manifests in association with exercise, acute illness with excessive catecholamine release, alcohol ingestion, altered fluid states, hypoxia, metabolic disturbance, or drug use (eg, caffeine, albuterol, theophylline, cocaine) is associated with automaticity or triggered activity. Digitalis intoxication is an important cause of atrial tachycardia, with triggered activity being the underlying mechanism.
Reentrant atrial tachycardia tends to occur in patients with structural heart disease, including ischemic, congenital, postoperative, and valvular disorders. Iatrogenic atrial tachycardias have become more common and typically result from ablative procedures in the left atrium. Several typical origination sites for these tachycardias have been identified, including the mitral isthmus (between the left lower pulmonary vein and mitral annulus), the roof of the left atrium, and, for reentry, around the pulmonary veins.
The most common reason for postablation tachycardias is gaps in the ablation lines, allowing for slow conduction and initiation reentry circuits or circuits excluded by the set of ablation lines. Typically, these patients have undergone an atrial fibrillation ablation procedure. This is true for catheter ablation and surgical epicardial ablation. Similarly, patients with prior surgical procedures involving the left atrium may have surgical incision lines and, hence, the potential for macroreentrant circuits.
MAT is often related to underlying illnesses, frequently occurring in patients experiencing an exacerbation of chronic obstructive pulmonary disease (Copd),  a pulmonary thromboembolism, an exacerbation of heart failure, or severe illness, especially under critical care with inotropic infusion. MAT is often associated with hypoxia and sympathetic stimulation. Digitalis toxicity also may be present in persons with MAT, with triggered activity as the mechanism.
Other underlying conditions that are commonly associated with MAT are the following:
Valvular heart disease
Unusual forms of atrial tachycardias can be seen in patients with an infiltrative process involving the pericardium and, by extension, the atrial wall.
Atrial tachycardia is relatively rare, constituting 5-15% of all SVTs. Atrial tachycardia has no known racial or ethnic predilection and no known predilection for either sex. There may be some association with pregnancy.
Atrial tachycardia may occur at any age, although it is more common in children and adults with congenital heart disease. MAT is a relatively infrequent arrhythmia, with a prevalence rate of 0.05-0.32% in patients who are hospitalized. It is predominantly observed in males and in older patients—in particular, elderly patients with multiple medical problems. The average age of patients from 9 studies was 72 years.
In patients with structurally normal heaRTS, atrial tachycardia is associated with a low mortality rate. However, tachycardia-induced cardiomyopathies have developed in patients with persistent or frequent atrial tachycardia. Patients with underlying structural heart disease, congenital heart disease, or lung disease are less likely to be able to tolerate atrial tachycardia. Other morbidity is associated with lifestyle changes and associated symptoms.
A study by Chung et al indicated that in patients with acute ischemic stroke and nonsustained atrial tachycardia, an enlarged left atrium is a risk factor for stroke recurrence. The study involved 252 patients, who were followed up for a mean period of 35 months. 
MAT itself is seldom life threatening. The condition is transient and resolves when the underlying condition improves. The prognosis depends on the prognosis of any comorbid disease.
Many patients with MAT have significant comorbidities, especially Copd and respiratory failure, that often require treatment in an intensive care unit. Consequently, a high mortality rate (up to 45%) is associated with this arrhythmia, although the mortality is not a direct consequence of the rhythm abnormality.
Potential complications of MAT include development of tachycardia-induced cardiomyopathy if the arrhythmia is persistent. Other complications include the following:
Atrial thrombi with embolization and subsequent stroke
Myocardial infarction from incongruous myocardial supply and demand
In the case of multifocal atrial tachycardia (MAT) related to medication, education regarding correct medication usage and the monitoring of such medications should be considered. In the case of a pulmonary source, education about prevention and recognition of developing pulmonary conditions may be helpful.
Weber R, Letsas KP, Arentz T, Kalusche D. Adenosine sensitive focal atrial tachycardia originating from the non-coronary aortic cusp. Europace. 2009 Jun. 11(6):823-6. [Medline].
McCord J, Borzak S. Multifocal atrial tachycardia. Chest. 1998 Jan. 113(1):203-9. [Medline].
Lennox EG. Cardiology. Arcara KM, Tschudy MM, eds. Johns Hopkins: The Harriet Lane Handbook. 19th ed. Philadelphia, PA: Mosby Elsevier Inc; 2012.
Knecht S, Veenhuyzen G, O’Neill MD, et al. Atrial tachycardias encountered in the context of catheter ablation for atrial fibrillation part ii: mapping and ablation. Pacing Clin Electrophysiol. 2009 Apr. 32(4):528-38. [Medline].
Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation. 1994 Sep. 90(3):1262-78. [Medline].
Law IH, Alam O, Bove EL, et al. Follow-up of a prospective surgical strategy to prevent intra-atrial reentrant tachycardia after the Fontan operation. Circ Arrhythm Electrophysiol. 2016 Dec. 9(12):[Medline].
Chung H, Joung B, Lee KY, et al. Left atrial volume index predicts recurrence of stroke in patients with nonsustained atrial tachycardia. J Stroke Cerebrovasc Dis. 2015 Oct. 24(10):2408-15. [Medline].
Nakasuka K, Miyamoto K, Noda T, et al. “Window Sliding” analysis combined with high-density and rapid electroanatomical mapping: its efficacy and the outcome of catheter ablation of atrial tachycardia. Heart Vessels. 2017 Mar 8. [Medline].
Tucker KJ, Law J, Rodriques MJ. Treatment of refractory recurrent multifocal atrial tachycardia with atrioventricular junction ablation and permanent pacing. J Invasive Cardiol. 1995 Sep. 7(7):207-12. [Medline].
Kastor JA. Multifocal atrial tachycardia. N Engl J Med. 1990 Jun 14. 322(24):1713-7. [Medline].
Cohen L, Kitzes R, Shnaider H. Multifocal atrial tachycardia responsive to parenteral magnesium. Magnes Res. 1988 Dec. 1(3-4):239-42. [Medline].
McCord JK, Borzak S, Davis T, Gheorghiade M. Usefulness of intravenous magnesium for multifocal atrial tachycardia in patients with chronic obstructive pulmonary disease. Am J Cardiol. 1998 Jan 1. 81(1):91-3. [Medline].
Parillo JE. Treating Multifocal Atrial Tachycardia (MAT) in a critical care unit: new data regarding verapamil and metoprolol. Update Crit Care Med. 1987. 2:3-5.
Arsura E, Lefkin AS, Scher DL, Solar M, Tessler S. A randomized, double-blind, placebo-controlled study of verapamil and metoprolol in treatment of multifocal atrial tachycardia. Am J Med. 1988 Oct. 85(4):519-24. [Medline].
Adcock JT, Heiselman DE, Hulisz DT. Continuous infusion diltiazem hydrochloride for treatment of multifocal atrial tachycardia (abstract). Clin Res. 1994. 42:430A.
Aronow WS, Plasencia G, Wong R. Effect of verapamil versus placebo on PAT and MAT. Current Ther Res. 1980. 27:823-29.
Hazard PB, Burnett CR. Verapamil in multifocal atrial tachycardia. Hemodynamic and respiratory changes. Chest. 1987 Jan. 91(1):68-70. [Medline].
Salerno DM, Anderson B, Sharkey PJ, Iber C. Intravenous verapamil for treatment of multifocal atrial tachycardia with and without calcium pretreatment. Ann Intern Med. 1987 Nov. 107(5):623-8. [Medline].
Kouvaras G, Cokkinos DV, Halal G, Chronopoulos G, Ioannou N. The effective treatment of multifocal atrial tachycardia with amiodarone. Jpn Heart J. 1989 May. 30(3):301-12. [Medline].
Kuralay E, Cingoz F, Kilic S, et al. Supraventricular tachyarrythmia prophylaxis after coronary artery surgery in chronic obstructive pulmonary disease patients (early amiodarone prophylaxis trial). Eur J Cardiothorac Surg. 2004 Feb. 25(2):224-30. [Medline].
Barranco F, Sanchez M, Rodriguez J, Guerrero M. Efficacy of flecainide in patients with supraventricular arrhythmias and respiratory insufficiency. Intensive Care Med. 1994. 20(1):42-4. [Medline].
[Guideline] Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016 Apr 5. 133(14):e471-505. [Medline]. [Full Text].
Lyan E, Toniolo M, Tsyganov A, et al. Comparison of strategies for catheter ablation of focal atrial tachycardia originating near the His bundle region. Heart Rhythm. 2017 Mar 1. [Medline].
Adam S Budzikowski, MD, PhD, FHRS Assistant Professor of Medicine, Division of Cardiovascular Medicine, Electrophysiology Section, State University of New York Downstate Medical Center, University Hospital of Brooklyn
Disclosure: Received consulting fee from Boston Scientific for speaking and teaching; Received honoraria from St. Jude Medical for speaking and teaching; Received honoraria from Zoll for speaking and teaching.
Disclosure: Nothing to disclose.
Jeffrey N Rottman, MD Professor of Medicine, Department of Medicine, Division of Cardiovascular Medicine, University of Maryland School of Medicine; Cardiologist/Electrophysiologist, University of Maryland Medical System and VA Maryland Health Care System
Disclosure: Nothing to disclose.
Mirna M Farah, MD Associate Professor of Pediatrics, University of Pennsylvania School of Medicine; Attending Physician, Division of Emergency Medicine, Children’s Hospital of Philadelphia
Mirna M Farah, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.
Dariusz Michałkiewicz, MD Head, Electrophysiology Department, Military Medical Institute, Poland
Disclosure: Nothing to disclose.
Brian Olshansky, MD Professor of Medicine, Department of Internal Medicine, University of Iowa College of Medicine
Brian Olshansky, MD is a member of the following medical societies: American Autonomic Society, American College of Cardiology, American College of Chest Physicians, American College of Physicians, American College of Sports Medicine, American Federation for Clinical Research, American Heart Association, Cardiac Electrophysiology Society, Heart Rhythm Society, and New York Academy of Sciences
Disclosure: Guidant/Boston Scientific Honoraria Speaking and teaching; Medtronic Honoraria Speaking and teaching; Guidant/Boston Scientific Consulting fee Consulting; Novartis Honoraria Speaking and teaching; Novartis Consulting fee Consulting
David A Peak, MD Assistant Residency Director of Harvard Affiliated Emergency Medicine Residency, Attending Physician, Massachusetts General Hospital; Consulting Staff, Department of Hyperbaric Medicine, Massachusetts Eye and Ear Infirmary
David A Peak, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Society for Academic Emergency Medicine, and Undersea and Hyperbaric Medical Society
Disclosure: Pfizer Salary Employment
Justin D Pearlman, MD, PhD, ME, MA Director of Advanced Cardiovascular imaging, Professor of Medicine, Professor of Radiology, Adjunct Professor, Thayer Bioengineering and Computer Science, Dartmouth-Hitchcock Medical Center
Justin D Pearlman, MD, PhD, ME, MA is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Federation for Medical Research, International Society for Magnetic Resonance in Medicine, and Radiological Society of North America
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Medscape Salary Employment
Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference
Disclosure: Nothing to disclose.
Grace M Young, MD Associate Professor, Department of Pediatrics, University of Maryland Medical Center
Disclosure: Nothing to disclose.